ArticleJournal of the American Heart Association2025
Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Consumption, and the Risk of Atrial Fibrillation: A Nationwide Population-Based Study.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- From liver to cardiovascular system: the MASLD-ASCVD continuum.Internal and emergency medicine · 2026Review
- Trends in atrial fibrillation/atrial flutter and cirrhosis-related mortality in the United States from 1999 to 2020: a CDC WONDER analysis.Annals of medicine and surgery (2012) · 2026Review
- Liver fibrosis burden and risk of incident arrhythmia in metabolic dysfunction-associated steatotic liver disease.Scientific reports · 2026Article
- Crosstalk Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Atrial Fibrillation: Shared Mechanism, Diagnostic Integration, and Management Implications.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe recent reclassification of steatotic liver disease into metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated alcohol-related liver disease has highlighted their potential cardiovascular implications. This study aimed to investigate the impact of MASLD and metabolic dysfunction-associated alcohol-related liver disease on the risk of newly diagnosed atrial fibrillation (AF).
methodsData from 362 285 participants who underwent a health screening in 2009 to 2010, sourced from the Korean National Health Insurance database, were identified, and we retrospectively analyzed their data through 2019. Excluding those with other liver diseases and heavy alcoholics, 206 455 participants with a fatty liver index were included. The primary outcome was newly diagnosed AF; associated conditions, such as ischemic stroke and heart failure, were also investigated. Participants were classified into 4 groups based on their steatotic liver disease status and alcohol consumption levels.
resultsOver a median follow-up of 9.6 years, 5335 participants were newly diagnosed with AF (2.74 per 1000 person-years). The risk of AF was significantly higher in patients with MASLD who did not consume alcohol (adjusted hazard ratio [aHR], 1.32 [95% CI, 1.23-1.41];
conclusionsMASLD is associated with incident AF. These findings suggest that metabolic dysfunction plays a more significant role in AF occurrence than the direct toxic effects of alcohol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.